EyePoint Pharmaceuticals, Inc. entered into an underwriting agreement on October 14, 2025, for a public offering of 11 million shares at $12.00 each, aiming to raise approximately $141 million for clinical development of DURAVYU™ and other initiatives. The offering closed on October 16, 2025.